Welcome to our dedicated page for Nano Labs SEC filings (Ticker: NA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nano Labs Ltd (NA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Nano Labs files annual reports on Form 20-F and current reports on Form 6-K, which are used to furnish press releases, unaudited consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations.
Recent Form 6-K filings incorporate by reference a range of documents into Nano Labs’ effective Form F-3 shelf registration statements. These include press releases on Web 3.0 infrastructure initiatives, crypto-asset reserve strategies involving BNB and BTC, share repurchase programs, at-the-market equity offerings, uplisting to the Nasdaq Global Market, and early repayment of convertible bonds. One Form 6-K also furnishes unaudited consolidated financial statements and related MD&A, along with Inline XBRL instance and taxonomy extension documents.
Through these filings, investors can track how Nano Labs describes its role as a Web 3.0 infrastructure and product solution provider, a fabless IC design company focused on HTC and HPC chips, and a participant in the crypto assets space. The filings also document changes to share structure, voting rights, and amendments to its memorandum and articles of association approved at shareholder meetings.
On Stock Titan, Nano Labs filings are updated as they are made available on EDGAR, and AI-powered summaries can help explain the contents of lengthy reports. Users can quickly see which filings relate to capital raising under Form F-3, which provide financial statements and MD&A, and which furnish key press releases that outline strategic directions in computing power and Web 3.0.
Nano Labs Ltd, a China-based foreign private issuer, furnished a Form 6-K for November 2025. The company attaches a press release as Exhibit 99.1 and formally incorporates that press release by reference into four existing registration statements on Form F-3 (including one filed as a post-effective amendment to a prior Form F-1). This means the information in the press release is now legally part of those shelf registration statements from the date of this report, unless later filings replace it.
Nano Labs Ltd, a foreign private issuer based in Hangzhou, China, furnished a Form 6-K for November 2025. The filing does not present new financial results but focuses on a legal and disclosure update.
The company attaches a press release as Exhibit 99.1 and formally incorporates this document by reference into four existing registration statements on Form F-3 and a post-effective amendment to a Form F-1 on Form F-3. From the date of this report, that press release becomes part of those registration statements unless later filings supersede it. The report is signed by Chairman and Chief Executive Officer Jianping Kong.
Nano Labs Ltd filed a Form 6-K to furnish a press release as Exhibit 99.1 and formally incorporate that document into several existing registration statements on Form F-3 and a post-effective amendment to Form F-1. This step ensures the press release is legally part of those shelf registration materials for U.S. investors.
Nano Labs Ltd filed a Form 6-K as a foreign private issuer for September 2025. The filing furnishes unaudited consolidated financial statements as of December 31, 2024 and June 30, 2025, along with results for the six months ended June 30, 2024 and 2025.
The 6-K also includes management’s discussion and analysis of financial condition and results of operations, and incorporates these materials by reference into three existing Form F-3 registration statements previously filed with the U.S. Securities and Exchange Commission.
Nano Labs Ltd Schedule 13D Amendment No.5 reports that Wlyl Ltd purchased 480,000 Class A ordinary shares in open-market transactions from August 21 to August 25, 2025 for investment purposes. As of August 25, 2025 the reporting persons collectively beneficially own 4,918,545 ordinary shares, which the filing states represents 20.9% of the outstanding ordinary shares on a converted-basis (23,571,833 shares). NLABS FUND PTE LTD. directly holds 1,888,342 Class A shares (8.0%), NlabsDAO Trust/JIANPING KONG LTD holds 2,370,391 shares (10.1%), and Wlyl Ltd/Lunyu Trust holds 659,812 shares (2.8%). The filing explains the two-class capital structure where each Class B share converts into one Class A and carries 30 votes per Class B share, creating pronounced voting leverage for Class B holders.
Nano Labs Ltd furnished a Form 6-K as a foreign private issuer, providing additional information to U.S. investors. The company states that the document attached as Exhibit 99.1 is incorporated by reference into its existing shelf registration statements on Form F-3, one initially filed on August 14, 2023 and another initially filed on August 4, 2025, so that this material becomes part of those offerings unless later superseded. The filing also lists a press release as Exhibit 99.1 and a sales agreement as Exhibit 99.2, indicating these materials are now formally on record with U.S. regulators.
Nano Labs Ltd files a prospectus supplement for an "at-the-market" offering of up to 10,000,000 Class A ordinary shares for aggregate proceeds up to US$45,000,000 at an assumed price of $4.50 per share (last reported Nasdaq sale on August 20, 2025). Before the offering the company had 23,571,833 ordinary shares outstanding (20,712,924 Class A and 2,858,909 Class B); after the offering up to 33,571,833 ordinary shares assuming full sale. Net tangible book value per share was presented as $3.46 and as-adjusted $3.73, with a decrease to new investors of $0.77. The company intends to use proceeds for a BNB and crypto asset reserve strategy, R&D and general corporate purposes. The supplement incorporates extensive risk disclosures highlighting cryptocurrency market volatility, regulatory and PRC-specific risks, supplier concentration, potential PCAOB inspection/delisting risk, dual-class share structure and other corporate governance and operational risks.